[1]Pyšná A, Bém R, Němcová A, et al. Endothelial progenitor cells biology in diabetes mellitus and peripheral arterial disease and their therapeutic potential[J]. Stem Cell Rev Rep, 2019,15:157-165. [2]Norgren L, Weiss N, Nikol S, et al. PLX-PAD cell treatment of critical limb ischaemia: rationale and design of the PACE trial[J]. Eur J Vasc Endovasc Surg, 2019,57:538-545. [3]Ledford KJ, Murphy N, Zeigler F, et al. Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases[J]. Stem Cell Res Ther, 2015,13;6:25. doi:10.1186/s13287-015-0007-3. [4]Liang TW, Jester A, Motaganahalli RL, et al. Autologous bone marrow mononuclear cell therapy for critical limb ischemia is effective and durable[J]. J Vasc Surg, 2016,63:1541-1545. [5]Altabas V, Altabas K, Kirigin L, et al. Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes[J]. Mech Ageing Dev, 2016,159:49-62. [6]Song Y, Yang J, Li T, et al. CD34+ cell-derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis[J]. Sci Adv, 2023,9:eadd2632. doi:10.1126/sciadv.add2632. [7]Zhu QQ, Li DL, He YY, et al. Advanced glycation end-products downregulate HoxA9EC through activation of nuclear factor Kappa B by reciprocal interaction[J]. J Vasc Res, 2017,54:226-234. [8]Xiao F, Qiu H, Zhou L, et al. WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation[J]. Glycobiology, 2013,23:524-535. [9]Wang Y, Fan L, Meng X, et al. Transplantation of IL-10-transfected endothelial progenitor cells improves retinal vascular repair via suppressing inflammation in diabetic rats[J]. Graefes Arch Clin Exp Ophthalmol, 2016,254:1957-1965. [10]Zhao Y, Yu B, Wang Y, et al. Ang-1 and VEGF: central regulators of angiogenesis[J]. Mol Cell Biochem, 2024:23. doi:10.1007/s11010-024-05010-3. [11]Saharinen P, Eklund L, Alitalo K, et al. Therapeutic targeting of the angiopoietin-TIE pathway. [J] Nat Rev Drug Discov, 2017,16:635-661. [12]Guan Y, Song X, Sun W, et al. Effect of hypoxia-induced microRNA-210 expression on cardiovascular disease and the underlying mechanism[J]. Oxid Med Cell Longev, 2019,2019:4727283. doi:10.1155/2019/4727283. [13]Ren CX, Leng RX, Fan YG, et al. MicroRNA-210 and its theranostic potential[J]. Expert Opin Ther Targets, 2016,20:1325-1338. [14]Canjuga D, Steinle H, Mayer J, et al. Homing of mRNA-modified endothelial progenitor cells to inflamed endothelium[J]. Pharmaceutics, 2022,14:1194. doi:10.3390/pharmaceutics14061194. [15]Zan T, Li H, Du Z, et al. Enhanced endothelial progenitor cell mobilization and function through direct manipulation of hypoxia inducible factor-1α[J]. Cell Biochem Funct, 2015,33:143-149.
|